Search This Blog

Friday, May 29, 2020

Celsion jumps after getting go-ahead for OVATION Phase 2

Celsion (NASDAQ:CLSNsurges 12% in premarket trading after the Data Safety Monitoring Board recommends that the company proceed to Phase 2 portion of its OVATION Study with the dose of 100 mg/m2.
The DSMB also determined that safety is satisfactory with an acceptable risk/benefit, and that patients tolerate up to 17 doses of GEN-1 during a course of treatment that lasts up to six months. No dose limiting toxicities were reported.
The OVATION 2 Study combines GEN-1, Celsion’s IL-12 gene-mediated immunotherapy, with standard-of-care neoadjuvant chemotherapy in patients newly diagnosed with Stage III/IV ovarian cancer.
https://seekingalpha.com/news/3578666-celsion-jumps-12-after-getting-dsmb-go-ahead-for-ovation-phase-2

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.